Back to News
Market Impact: 0.2
Abbott Laboratories Reaffirms FY26 Adj. EPS Outlook
Source: Nasdaq
Corporate EarningsCorporate Guidance & Outlook
Abbott Laboratories reported third-quarter financial results and provided adjusted earnings guidance for Q4. The company reaffirmed its adjusted earnings outlook for full-year 2026; the article excerpt provides no figures or changes to guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ABT0.10
More News
- Stock Movers: Super Micro Computer, SpaceX, Abbot Labs (Podcast)
- Our top 10 things to watch in the stock market Wednesday
- Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
- Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
- Meta put out an ambitious roadmap to Muse monetization after strong quarter and guide
- Why the stock market’s fragile calm faces a major test starting Friday
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund